Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

Merck's phase IIb/III BRUNELLO trial met its primary endpoint: both 0.5-mg and 0.8-mg remigromig doses were non-inferior to 0.5-mg ranibizumab on best-corrected visual-acuity improvement at week 52 in diabetic macular edema. The first-in-class Wnt-pathway antibody was generally well tolerated, but showed higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and adverse-event discontinuations than ranibizumab, requiring further analysis. The result advances a drug acquired through Merck's 2024 EyeBio deal, with a second pivotal DME study ongoing and detailed results due at an October 2026 ophthalmology meeting.

Analysis

The read-through for MRK is strategic rather than near-term EPS material: ophthalmology can become a post-Keytruda durability asset, but only if efficacy translates into differentiated dosing, durability, or outcomes in anti-VEGF inadequate responders. Simple non-inferiority does not support meaningful share capture in a market increasingly anchored by lower-cost bevacizumab and durable branded agents from RHHBY/REGN and SNY; a safety imbalance raises the commercial bar further. The relevant valuation catalyst is therefore not this headline but the full safety, subgroup, and injection-burden dataset at AAO, followed by confirmation in BAROLO over the next 6-18 months.

Competitive risk falls most directly on REGN and RHHBY only if remigromig demonstrates benefit in refractory patients without worsening retinal complications. More plausibly, MRK's two ophthalmology mechanisms create a portfolio-option value: physicians could segment patients by biology, while MRK gains negotiating leverage with retina practices and payers. That optionality is real but currently too early to underwrite in consensus revenue; the asset's acquisition economics and future development spend matter more than peak-sales narratives.

Contrarian view: MRK has already materially rerated, so investors may treat a first positive study as evidence that ophthalmology replaces lost Keytruda economics. The disclosed discontinuation and hemorrhage signal can instead delay regulatory review, narrow labeling, or require risk-mitigation language, limiting uptake precisely in the higher-risk refractory population where differentiation is most valuable. No read-through exists for ANIK, PGEN, or RGEN; their inclusion is promotional noise rather than a fundamental linkage.

Key Decisions for Investors

• Maintain MRK at market weight; do not chase a data-driven move over the next days. Reassess after AAO 2026 only if absolute retinal-complication and discontinuation rates, dose-response, and refractory-patient outcomes support a clinically meaningful benefit.
• Set a 1-3 month event watch on MRK: initiate a tactical long only on evidence that BAROLO enrollment/execution remains on schedule and management quantifies a clean safety explanation. Thesis is falsified by a guidance increase in development expense without a credible path to differentiated labeling.
• For an ophthalmology competitive hedge, monitor REGN and RHHBY rather than shorting now. Consider a small MRK long / REGN short pair only if subsequent data show comparable vision gains with a materially reduced treatment burden and no persistent safety gap; absent that, the pair lacks catalyst asymmetry.
• Exclude ANIK, PGEN, and RGEN from any trade basket tied to this event; there is no identifiable product, supply-chain, or customer exposure linking their earnings to MRK's retinal pipeline.